Related Experiment Video
Updated: Jun 16, 2026
05:42
Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
Published on: January 3, 2020
Somatostatin analogues for pancreatic surgery
Kurinchi Selvan Gurusamy1, Rahul Koti, Giuseppe Fusai
1University Department of Surgery, Royal Free Hospital and University College School of Medicine, 9th Floor, Royal Free Hospital, Pond Street, London, UK, NW3 2QG.
The Cochrane Database of Systematic Reviews
|February 19, 2010
Summary
Synthetic somatostatin analogues reduce postoperative complications in pancreatic surgery but do not affect mortality. Routine use is recommended for malignancy, shortening hospital stays, but not for other indications.
Area of Science:
- Gastroenterology and Surgical Oncology
- Pharmacology and Drug Efficacy
Background:
- Pancreatic resections carry significant risks, with morbidity rates of 30-60% and mortality of 5%.
- The prophylactic use of synthetic somatostatin analogues to mitigate these risks is debated among surgeons.
Purpose of the Study:
- To evaluate the efficacy of routine prophylactic somatostatin analogue administration in pancreatic surgery.
- To determine if these analogues reduce postoperative complications and mortality.
Main Methods:
- Systematic review and meta-analysis of 17 randomized controlled trials involving 2143 patients.
- Data extraction and analysis using fixed-effect and random-effects models.
- Risk ratios and mean differences with 95% confidence intervals were calculated.
Main Results:
- Somatostatin analogues significantly reduced overall postoperative complications (RR 0.71; 95% CI 0.62 to 0.82) and pancreatic fistulas (RR 0.64; 95% CI 0.53 to 0.78).
- No significant differences were observed in perioperative mortality, re-operation rates, or overall hospital stay.
- A subgroup analysis indicated a shorter hospital stay for patients with malignant pancreatic conditions (MD -7.57; 95% CI -11.29 to -3.84).
Conclusions:
- Somatostatin analogues effectively decrease perioperative complications and pancreatic fistulas but do not impact mortality.
- Routine use is recommended for pancreatic resections due to malignancy, leading to shorter hospital stays.
- Evidence does not support routine use for pancreatic surgeries with other indications; further high-quality trials are needed.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...